Medipharma, a Japanese site management organization (SMO), has initiated bankruptcy proceedings after it was found to have violated good clinical practice (GCP) regulations, including by falsifying clinical trial data. The Tokyo District Court approved the initiation of the proceedings as…
To read the full story
Related Article
- Medipharma Altered Data in at Least 7 Clinical Trials: MHLW
November 28, 2023
- Medipharma Might Face Administrative Penalty over Trial Data Tampering
October 18, 2023
BUSINESS
- FDA Extends Review of Capricor’s DMD Cell Therapy by 3 Months
August 26, 2026
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





